Zymeworks' collaborator BeOne Medicines secured the approval under the terms of their Asia-Pacific licence and partnership ...

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group.

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...